While these studies underscore the potential of AAV-CLN2 or AAV-CLN6 as a treatment modality for LINCL following intracranial or i.t. administration, respectively, further research is warranted to optimize dosing regimens and assess safety profiles, particularly considering alternative routes of administration. The gene discussed is TPP1; the disease is late infantile neuronal ceroid lipofuscinosis.